Abstract
Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Presently, cytological evaluation of fine needle aspiration biopsy (FNAB) which is known as invasive recognition assay, is the standard diagnostic method for the diagnosis of malignant thyroid tumors. Frequent studies have suggested that using the molecular biomarkers of thyroid cancer tissue alongside cytological examination, increase the accuracy of diagnostic tests. Also, these agents could be beneficial for effective target therapy and personalize medicine. In this review, the molecular biomarkers that are involved in anaplastic thyroid carcinoma in four category (gene mutation profile, epigenetic profile, microRNA profile and cancer stem cell markers) were summarized.
Keywords: Anaplastic thyroid carcinoma, molecular biomarkers, gene mutation profile, epigenetic profile, microRNA profile, cancer stem cell markers.
Current Molecular Medicine
Title:Molecular Biomarkers of Anaplastic Thyroid Carcinoma
Volume: 17 Issue: 3
Author(s): F. Bozorg-Ghalati*M. Hedayati
Affiliation:
- Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Anaplastic thyroid carcinoma, molecular biomarkers, gene mutation profile, epigenetic profile, microRNA profile, cancer stem cell markers.
Abstract: Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Presently, cytological evaluation of fine needle aspiration biopsy (FNAB) which is known as invasive recognition assay, is the standard diagnostic method for the diagnosis of malignant thyroid tumors. Frequent studies have suggested that using the molecular biomarkers of thyroid cancer tissue alongside cytological examination, increase the accuracy of diagnostic tests. Also, these agents could be beneficial for effective target therapy and personalize medicine. In this review, the molecular biomarkers that are involved in anaplastic thyroid carcinoma in four category (gene mutation profile, epigenetic profile, microRNA profile and cancer stem cell markers) were summarized.
Export Options
About this article
Cite this article as:
Bozorg-Ghalati F. *, Hedayati M. , Molecular Biomarkers of Anaplastic Thyroid Carcinoma, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170822102417
DOI https://dx.doi.org/10.2174/1566524017666170822102417 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Design of Cathepsin K Inhibitors for Osteoporosis
Current Topics in Medicinal Chemistry Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Lectin Microarrays: A Powerful Tool for Glycan-Based Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Editorial Review 2017
Current Radiopharmaceuticals Steroid Receptor Ligands for Breast Cancer Targeting: An Insight into Their Potential Role As Pet Imaging Agents
Current Medicinal Chemistry Plant Glutathione Transferases: Structure, Antioxidant Catalytic Function and in planta Protective Role in Biotic and Abiotic Stress
Current Chemical Biology The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs)
Recent Patents on Anti-Cancer Drug Discovery The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer
Current Pharmaceutical Biotechnology Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Biological Evaluation of <sup>99m</sup>Tc-HYNIC-EDDA/tricine-(Ser)<sub>3</sub>-D4 Peptide for Tumor Targeting
Current Radiopharmaceuticals An Update in the Management of Obesity: The Weight of CNS Targets
Recent Patents on CNS Drug Discovery (Discontinued)